Literature DB >> 18374191

Quinone oxidoreductases and vitamin K metabolism.

Xing Gong1, Ramana Gutala, Anil K Jaiswal.   

Abstract

Vitamin K1, K2, and K3 are essential nutrients associated with blood clotting and bone metabolism. Quinone oxidoreductases [NAD(P)H:quinone oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (NQO2)] are among the selected enzymes that catalyze reduction of vitamin K to vitamin K hydroquinone. NQO1 catalyzes high affinity reduction of vitamin K3 but has only weak affinity for reduction of vitamin K1 and K2. Vitamin K hydroquinone serves as a cofactor for vitamin K gamma-carboxylase that catalyzes gamma-carboxylation of specific glutamic acid residues in Gla-factors/proteins leading to their activation and participation in blood clotting and bone metabolism. Concomitant with Gla modification, a reduced vitamin K molecule is converted to vitamin K epoxide, which is converted back to vitamin K by the enzyme vitamin K epoxide reductase to complete vitamin K cycle. Vitamin K is also redox cycled. One-electron reduction of vitamin K3 leads to the formation of semiquinone that in the presence of oxygen is oxidized back to vitamin K3. Oxygen is reduced to generate reactive oxygen species (ROS) that causes oxidative stress and cytotoxicity. Vitamin K is used as radiation sensitizer or in mixtures with other chemotherapeutic drugs to treat several types of cancer. ROS generated in redox cycling contributes to anticancer activity of vitamin K. NQO1 competes with enzymes that redox cycle vitamin K and catalyzes two-electron reduction of vitamin K3 to hydroquinone. This skips formation of semiquinone and ROS. Therefore, NQO1 metabolically detoxifies vitamin K3 and protects cells against oxidative stress and other adverse effects. On the contrary, NQO2 catalyzes metabolic activation of vitamin K3 leading to cytotoxicity. The role of NQO1 and NQO2 in metabolic detoxification and/or activation of vitamin K1 and K2 remains to be determined. Future studies are also required to identify the enzymes that catalyze high affinity reduction of vitamin K1 and K2 to hydroquinone for use in gamma-carboxylation reactions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18374191     DOI: 10.1016/S0083-6729(07)00005-2

Source DB:  PubMed          Journal:  Vitam Horm        ISSN: 0083-6729            Impact factor:   3.421


  23 in total

1.  Cellular stress responses: cell survival and cell death.

Authors:  Simone Fulda; Adrienne M Gorman; Osamu Hori; Afshin Samali
Journal:  Int J Cell Biol       Date:  2010-02-21

2.  Rapid generation of hydrogen peroxide contributes to the complex cell death induction by the angucycline antibiotic landomycin E.

Authors:  Rostyslav R Panchuk; Lilya V Lehka; Alessio Terenzi; Bohdan P Matselyukh; Jürgen Rohr; Amit K Jha; Theresa Downey; Iryna J Kril; Irene Herbacek; Sushilla van Schoonhoven; Petra Heffeter; Rostyslav S Stoika; Walter Berger
Journal:  Free Radic Biol Med       Date:  2017-02-09       Impact factor: 7.376

3.  Functional Study of the Vitamin K Cycle Enzymes in Live Cells.

Authors:  J-K Tie; D W Stafford
Journal:  Methods Enzymol       Date:  2016-11-22       Impact factor: 1.600

4.  Functional study of the vitamin K cycle in mammalian cells.

Authors:  Jian-Ke Tie; Da-Yun Jin; David L Straight; Darrel W Stafford
Journal:  Blood       Date:  2011-01-14       Impact factor: 22.113

Review 5.  Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis.

Authors:  Martin J Shearer; Paul Newman
Journal:  J Lipid Res       Date:  2014-01-31       Impact factor: 5.922

6.  Decreased expression of vitamin K epoxide reductase complex subunit 1 in kidney of patients with calcium oxalate urolithiasis.

Authors:  Bo Hu; Tao Wang; Zhuo Liu; Xiaolin Guo; Jun Yang; Jihong Liu; Shaogang Wang; Zhangqun Ye
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-12-16

7.  Involvement of VKORC1 in the inhibition of calcium oxalate crystal formation in HK-2 cells.

Authors:  Bo Hu; Hao-Ran Wu; Zhi-Yong Ma; Zhuan-Chang Wu; Ying-Mei Lu; Guo-Wei Shi
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-06-18

8.  Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves.

Authors:  Jee-Eun Chung; Byung Chul Chang; Kyung Eun Lee; Joo Hee Kim; Hye Sun Gwak
Journal:  Eur J Clin Pharmacol       Date:  2015-08-11       Impact factor: 2.953

9.  Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans.

Authors:  Adam Bress; Shitalben R Patel; Minoli A Perera; Richard T Campbell; Rick A Kittles; Larisa H Cavallari
Journal:  Pharmacogenomics       Date:  2012-12       Impact factor: 2.533

10.  The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations.

Authors:  Sophia Sominsky; Michael Korostishevsky; Daniel Kurnik; Eleni Aklillu; Yoram Cohen; Gie Ken-Dror; Ronen Loebstein; Hillel Halkin; Eva Gak
Journal:  J Appl Genet       Date:  2014-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.